Australiadrgapp

Clarity Pharmaceuticals (ASX:CU6) received positive guidance from the US FDA to proceed with a pivotal Phase 3 trial of its 64Cu-SARTATE diagnostic agent in patients with neuroendocrine tumours.

President Donald Trump is expected have his administration move to reclassify marijuana as a less dangerous drug, according to people familiar with the matter. This has been good news for pot stocks. Nathan Dean of Bloomberg Intelligence has more.